Kepler Capital analyst Dariusz Ubik upgraded Grifols SA (GRFS – Research Report) to a Buy on September 26 and set a price target of EUR19.40. The company’s shares closed yesterday at $6.60.
According to TipRanks, Ubik is ranked #6212 out of 7814 analysts.
Grifols SA has an analyst consensus of Moderate Buy, with a price target consensus of $15.18.
See the top stocks recommended by analysts >>
GRFS market cap is currently $5.91B and has a P/E ratio of 5.97.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
Read More on GRFS:
